1082040-43-4

Basic information

• Product Name: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester
• Synonyms: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester;1H-Indole-4-carboxylic acid, 6-fluoro-, Methyl ester;Methyl 6-fluoro-1H-indole-4-carboxylate;6-Fluoro indole-4-Methylcarboxylate;methyl 6-Fluoroindole-4-carboxylate;Rucaparib Intermediate 2
• CAS NO: 1082040-43-4
• Molecular Formula: C₁₀H₈FNO₂
• Molecular Weight: 193
• Mol File: 1082040-43-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 343.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.341±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.20±0.30(Predicted)
• CAS DataBase Reference: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(1082040-43-4)
• EPA Substance Registry System: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(1082040-43-4)

Safety Data

• Hazardous Substances Data: 1082040-43-4(Hazardous Substances Data)

Usage

Uses

6-Fluoro-1H-indole-4-carboxylic acid methyl ester (CAS# 1082040-43-4) is an indole derivative and a useful building block, used in the synthesis of PARP Inhibitors, and drug intermediates such as the anti-?ovarian cancer drug, rucaparib.

Upstream product

• 697739-03-0 5-fluoro-2-methyl-3-nitrobenzoic acid methyl ester 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 850462-64-5 5-fluoro-2-methyl-3-nitrobenzoic acid 
• 175278-29-2 5-fluoro-2-methylbenzoic acid methyl ester 

Downstream Products

• 3891-07-4 N-(2-Hydroxyethyl)phthalimide 
• 1408282-25-6 3-(2-(phthalimido)ethyl)-6-fluoro-1H-indole-4-carboxylic acid methyl ester 
• 283173-50-2 Rucaparib 
• 1408282-26-7 6-fluoro-3,10-diazatricyclo[6.4.1.0^4,13]trideca-1,4⁽¹³⁾,5,7-tetraen-9-one 

Relevant articles and documents

Multkilogram scale-up of a reductive alkylation route to a novel PARP inhibitor

Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer. A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale. In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome. The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination. In addition to these issues, changing from intravenous to oral delivery required a new salt form and therefore a new crystallization procedure. This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.

Preparation method of ovarian cancer resistance medicine Rucaparib key intermediate

The invention discloses a preparation method of an ovarian cancer resistance medicine Rucaparib key intermediate, and relates to preparation of medical intermediates. A compound 1 takes methyl alcoholand cyclohexane as solvents, toluenesulfonic acid serve